The two companies will provide an end-to-end solution for sponsors needing precise, reliable sleep architecture data in therapeutic trials.
Sleep diagnostics company SOMNOmedics AG and neurophysiological biomarker solutions and services company Cognision have entered into a strategic partnership to use SOMNOmedics’ polysomnography (PSG) solutions in pharmaceutical-sponsored clinical trials.
The partnership leverages Cognision’s expertise in providing neurophysiological assessments in regulated research environments with SOMNOmedics’ PSG technology. Together, the two companies will provide an end-to-end solution for sponsors needing precise, reliable sleep architecture data in therapeutic trials.
According to Cognision, this will empower pharma sponsors to integrate robust sleep biomarkers into trials of drugs that treat abnormal sleep conditions or that may interfere with healthy sleep with the same confidence and performance that they expect from Cognision’s electroencephalography and event-related potential biomarkers.
“Sleep endpoints are becoming increasingly important in CNS [central nervous system] drug development, from neurodegeneration and neuropsychiatric disorders to pain and emerging psychedelic therapies,” says Igor Korolev, DO, PhD, vice president of neuroscience and digital health for Cognision, in a release. “This partnership delivers best-in-class PSG solutions, streamlined deployment, centralized data management, and highly reproducible automated analysis—without the complexity, risk, and delays often seen in CNS biomarker trials.”
SOMNOmedics PSG systems have adaptability to both inpatient and home use—giving sponsors options for decentralized clinical trials. All PSG data will be managed within Cognision’s cloud-based Clinical Trial Data Management System (CTMS), providing near real-time sponsor access for faster decision making and adaptive trial designs.
“This is not just about providing equipment—it’s about ensuring every site, patient, and data point meets the industry’s highest standards,” says Denise Frahley, SOMNOmedics director of US sales, in a release. “Together, our operational and technical innovations set a new benchmark for sleep measurement in pharmaceutical research.”
